- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01759654
A Trial to Assess the Immunogenicity and Safety of the Trivalent Virosomal Influenza Vaccine, Formulation of 2012-2013, in Non-Elderly Adults and Elderly Subjects
12. juli 2018 oppdatert av: Adimmune Corporation
This is an open study of the use of AdimFlu-V (2012-2013 season) vaccine in non-elderly and elderly subjects.
All participates will receive one dose of vaccine (0.5 ml) by intramuscular injection into the upper arm.
Safety outcomes included immediate reactions at the time of vaccination, solicited local and systemic reactions for 7 days, unsolicited adverse events for 28 days, and serious adverse events.
Sera prepared from blood samples will be collected from each subject immediately prior to, and 28 days after vaccination.
Anti-hemagglutinin (HA) antibody titers will be determined using the WHO hemagglutination inhibition reference technique.
The central laboratory who is responsible for antibody titrations will not be aware of the background of blood samples (e.g., pre- or post-serum), it is also called observer-blinded.
All participates will be followed, either by clinical visit or by telephone contact, for 8 weeks after the vaccination for safety reasons.
Studieoversikt
Studietype
Intervensjonell
Registrering (Faktiske)
120
Fase
- Fase 3
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Taipei, Taiwan
- National Taiwan University Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Males and non-pregnant females and aged no less than 18 years;
- Willing and able to adhere to visit schedules and all study requirements;
- Subjects are willing to provide the signed study-specific informed consent.
Exclusion Criteria:
- Subject or his/her family is employed by the participated hospital;
- Subjects received influenza vaccine within the previous 6 months;
- History of hypersensitivity to eggs or hen's protein, polymyxin B, or neomycin, or similar pharmacological effects to study vaccine;
- Personal or family history of Guillain-Barré Syndrome;
- An acute febrile illness within 1 week prior to vaccination;
- Current upper respiratory illness, including the common cold or nasal congestion within 72 hours;
- Subjects with influenza-like illness as defined by the presence of fever (temperature no less than 38°C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;
- Female subjects who are pregnant, lactating or likely to become pregnant during the study; women of childbearing potential disagree to use an acceptable method of contraception (e.g., hormonal contraceptives, intrauterine device (IUD), barrier device or abstinence) throughout the study;
- Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before study vaccination;
- Immunodeficiency, or under immunosuppressive treatment;
- Receipt of live virus vaccine within 1 month prior to study vaccination or expected receipt within 1 month of study vaccination; receipt of any inactivated vaccine within 2 weeks prior to study vaccination or expected receipt within 1 month of study vaccination;
- Receipt of any blood products, including immunoglobulin in the prior 3 months;
- Underlying condition in the investigators' opinion may interfere with evaluation of the vaccine;
- Significant chronic illness for which inactivated influenza vaccine is recommended or commonly used.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: AdimFlu-V
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
The primary objective is to evaluate the immune response (i.e. HAI titer) in subjects after administration of influenza vaccine for 2012-2013 season.
Tidsramme: Change from baseline for HAI titer at 21 days post immunization
|
Serum samples will be obtained prior to vaccination, and 3 weeks post vaccination.
Serum samples will be tested for anti-hemagglutinin (HA) antibodies by hemagglutination inhibition (HAI), and assays will be performed at Adimmune Corporation designated central laboratory.
|
Change from baseline for HAI titer at 21 days post immunization
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Number of participants reporting reactogenicity events
Tidsramme: up to 7 days after vaccination
|
Reactogenicity events are pre-specified adverse events systematically recorded on diary cards (a grid of check boxes for each event and each day) during the immediate post-vaccination period by all participants.
In general, reactogenicity events will be recorded for 7 days after vaccination.
The selection of the events to be collected systematically is based on events expected to occur with wild-type influenza infection including fever (≥38°C), runny nose or nasal congestion, cough, sore throat, muscle aches, headache, vomiting, nausea and malaise.
Furthermore, the local (injection site) reactions will also be evaluated that include soreness/pain, swelling, redness, ecchymosis and limitation of arm motion.
|
up to 7 days after vaccination
|
Number of participants reporting serious and non-serious adverse events
Tidsramme: Up to 8 weeks after vaccination.
|
In regard to the long term safety of the study vaccine, the significant and/or serious/non-serious adverse event(s) will be recorded during the 8 weeks follow up after vaccination.
|
Up to 8 weeks after vaccination.
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
24. oktober 2012
Primær fullføring (Faktiske)
25. desember 2012
Studiet fullført (Faktiske)
1. mars 2013
Datoer for studieregistrering
Først innsendt
17. desember 2012
Først innsendt som oppfylte QC-kriteriene
27. desember 2012
Først lagt ut (Anslag)
3. januar 2013
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. juli 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
12. juli 2018
Sist bekreftet
1. juli 2018
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- FLUV12T13A
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på AdimFlu-V
-
Adimmune CorporationFullført
-
National Cheng-Kung University HospitalUkjentKronisk nyre sykdom | Immunogenisitet og negativ medikamentell effekt av vaksiner InfluensaTaiwan
-
Adimmune CorporationFullført
-
Adimmune CorporationFullført
-
Adimmune CorporationFullført
-
Adimmune CorporationFullført
-
Livzon Pharmaceutical Group Inc.Aktiv, ikke rekrutterende
-
Inossia ABUppsala University; EIT HealthRekrutteringVertebral kompresjonsbruddSpania, Tyskland, Canada, Polen
-
Immunitor LLCUkjentGlioblastoma Multiforme | HjernegliomMongolia
-
PepTcell LimitedFullført